Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Pharmacotherapy in COVID-19; A narrative review for emergency providers
Nikita Mehta, Maryann Mazer‐Amirshahi, Nour Alkindi, et al.
The American Journal of Emergency Medicine (2020) Vol. 38, Iss. 7, pp. 1488-1493
Open Access | Times Cited: 120

Showing 1-25 of 120 citing articles:

Individuals with obesity and COVID‐19: A global perspective on the epidemiology and biological relationships
Barry M. Popkin, Shufa Du, William D. Green, et al.
Obesity Reviews (2020) Vol. 21, Iss. 11
Open Access | Times Cited: 1072
Update on the effectiveness of COVID-19 vaccines on different variants of SARS-CoV-2
Negar Firouzabadi, Parisa Ghasemiyeh, Fatemeh Moradishooli, et al.
International Immunopharmacology (2023) Vol. 117, pp. 109968-109968
Open Access | Times Cited: 78
Immunotherapeutic approaches to curtail COVID-19
Hajar Owji, Manica Negahdaripour, Nasim Hajighahramani
International Immunopharmacology (2020) Vol. 88, pp. 106924-106924
Open Access | Times Cited: 75
Nanoceria as a possible agent for the management of COVID-19
Prince Allawadhi, Amit Khurana, Sachin Allwadhi, et al.
Nano Today (2020) Vol. 35, pp. 100982-100982
Open Access | Times Cited: 74
Luteolin and abyssinone II as potential inhibitors of SARS-CoV-2: an in silico molecular modeling approach in battling the COVID-19 outbreak
Mohammad Mahfuz Ali Khan Shawan, Sajal Kumar Halder, Md. Ashraful Hasan
Bulletin of the National Research Centre/Bulletin of the National Research Center (2021) Vol. 45, Iss. 1
Open Access | Times Cited: 73
COVID-19 associated myocarditis: A systematic review
William Haussner, Antonio P. DeRosa, Danielle Haussner, et al.
The American Journal of Emergency Medicine (2021) Vol. 51, pp. 150-155
Open Access | Times Cited: 67
Races of small molecule clinical trials for the treatment of COVID‐19: An up‐to‐date comprehensive review
Suwen Hu, Songwei Jiang, Qi Xiang, et al.
Drug Development Research (2021) Vol. 83, Iss. 1, pp. 16-54
Open Access | Times Cited: 64
Immune responses in mildly versus critically ill COVID-19 patients
Hamid Nasrollahi, Atefe Ghamar Talepoor, Zahra Saleh, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 42
A Review of Treatment of Coronavirus Disease 2019 (COVID-19): Therapeutic Repurposing and Unmet Clinical Needs
Po‐Lin Chen, Nan–Yao Lee, Cong-Tat Cia, et al.
Frontiers in Pharmacology (2020) Vol. 11
Open Access | Times Cited: 61
Development and validation of a sensitive, fast and simple LC-MS / MS method for the quantitation of favipiravir in human serum
Duygu Eryavuz Onmaz, Sedat Abuşoğlu, Mustafa Onmaz, et al.
Journal of Chromatography B (2021) Vol. 1176, pp. 122768-122768
Open Access | Times Cited: 56
Safety of Hydroxychloroquine Among Outpatient Clinical Trial Participants for COVID-19
Sarah M Lofgren, Melanie R. Nicol, Ananta Bangdiwala, et al.
Open Forum Infectious Diseases (2020) Vol. 7, Iss. 11
Open Access | Times Cited: 48
Is Nanotechnology Helping in the Fight Against COVID-19?
Valéria Maria de Oliveira Cardoso, Bruna Juliana Moreira, Edson José Comparetti, et al.
Frontiers in Nanotechnology (2020) Vol. 2
Open Access | Times Cited: 40
Fluoxetine Can Inhibit SARS-CoV-2 In Vitro
Arthur Dechaumes, Magloire Pandoua Nekoua, Sandrine Belouzard, et al.
Microorganisms (2021) Vol. 9, Iss. 2, pp. 339-339
Open Access | Times Cited: 40
Treatment and prevention strategies for the COVID 19 pandemic: A review of immunotherapeutic approaches for neutralizing SARS-CoV-2
Pravas Kumar Baral, Yin Jiang, Michael N.G. James
International Journal of Biological Macromolecules (2021) Vol. 186, pp. 490-500
Open Access | Times Cited: 33
Randomized controlled trial of favipiravir, hydroxychloroquine, and standard care in patients with mild/moderate COVID-19 disease
Manaf AlQahtani, Nitya Kumar, Dhuha Aljawder, et al.
Scientific Reports (2022) Vol. 12, Iss. 1
Open Access | Times Cited: 28
Identification of a New Potential SARS-COV-2 RNA-Dependent RNA Polymerase Inhibitor via Combining Fragment-Based Drug Design, Docking, Molecular Dynamics, and MM-PBSA Calculations
Mahmoud A. El Hassab, Aly A. Shoun, Sara T. Al‐Rashood, et al.
Frontiers in Chemistry (2020) Vol. 8
Open Access | Times Cited: 37
Remdesivir use in the coronavirus disease 2019 pandemic: A mini-review
Chih‐Jen Yang, Yu-Jui Wei, Hsu-Liang Chang, et al.
Journal of Microbiology Immunology and Infection (2020) Vol. 54, Iss. 1, pp. 27-36
Open Access | Times Cited: 34
Review on therapeutic targets for COVID-19: insights from cytokine storm
Mário Luciano de Mélo Silva Júnior, Lívia Maria Alves de Souza, Renata Ellen Maria Carvalho Dutra, et al.
Postgraduate Medical Journal (2020) Vol. 97, Iss. 1148, pp. 391-398
Open Access | Times Cited: 34
Remdesivir—Bringing Hope for COVID-19 Treatment
Naser F. Al‐Tannak, Ladislav Novotný, Adel Al‐Hunayan
Scientia Pharmaceutica (2020) Vol. 88, Iss. 2, pp. 29-29
Open Access | Times Cited: 33
Experimental Pharmacotherapy for COVID-19: The Latest Advances
Pasquale Pagliano, Giuliana Scarpati, Carmine Sellitto, et al.
Journal of Experimental Pharmacology (2021) Vol. Volume 13, pp. 1-13
Open Access | Times Cited: 30
Possible therapeutic agents for COVID-19: a comprehensive review
Khaled Mosaad Elhusseiny, Fatma Abd‐Elshahed Abd‐Elhay, Mohamed Gomaa Kamel
Expert Review of Anti-infective Therapy (2020) Vol. 18, Iss. 10, pp. 1005-1020
Closed Access | Times Cited: 30
COVID-19 associated complications and potential therapeutic targets
Jasmin Monpara, Srushti Sodha, Pardeep Kumar Gupta
European Journal of Pharmacology (2020) Vol. 886, pp. 173548-173548
Open Access | Times Cited: 30
Cell therapy strategies for COVID-19: Current approaches and potential applications
Mark M. Zaki, Emal Lesha, Khaled Saïd, et al.
Science Advances (2021) Vol. 7, Iss. 33
Open Access | Times Cited: 24
Main and papain-like proteases as prospective targets for pharmacological treatment of coronavirus SARS-CoV-2
Larysa V. Yevsieieva, Kateryna Lohachova, Alexander Kyrychenko, et al.
RSC Advances (2023) Vol. 13, Iss. 50, pp. 35500-35524
Open Access | Times Cited: 10
Management of Patients With COVID-19 During the Pandemic: A Retrospective Cohort Study From a Tertiary Care Centre in Mumbai, India
Neeraj Kumar Tulara, Swapnil Mehta, Vimal Pahuja, et al.
Cureus (2025)
Open Access
Page 1 - Next Page

Scroll to top